POSB403 Reimbursed Cost for Monoclonal Antibodies in Bulgaria: A Case with Adalimumab and Pembrolizumab

Autor:	M Kamusheva, V Georgieva, L Marinov, E Boncheva, G Petrova
Rok vydání:	2022
Předmět:	Health Policy Public Health Environmental and Occupational Health
Zdroj:	Value in Health. 25:S259
ISSN:	1098-3015
DOI:	10.1016/j.jval.2021.11.1266
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::28450297f21d47bd182197162ebb567d https://doi.org/10.1016/j.jval.2021.11.1266 Zobrazit plný text záznamu Full Text from ScienceDirect